
Phanes Therapeutics: Innovating in immuno-oncology and eye disease drug discovery and development.
Phanes Therapeutics, Inc., founded with a mission to become a major source of innovation in the biopharma industry, focuses on drug discovery and early development in immuno-oncology and eye disease. The company leverages disruptive technologies and revolutionary approaches to open new possibilities in drug discovery, aiming to address unmet medical needs and improve patient outcomes.
Notable affiliated individuals and investors include experienced scientists and industry veterans who drive the company's innovative efforts. Phanes Therapeutics has achieved significant milestones in its research and development programs, contributing to advancements in immuno-oncology therapies. The company's impact is marked by its commitment to pioneering new treatments that have the potential to transform patient care in critical therapeutic areas.

Phoenicis

Pheast Therapeutics
pheast.com

Thesan Pharmaceuticals
thesanpharma.com

PineTree Therapeutics
pinetreetx.com

Visiox
visioxpharma.com

NanoPharmaceuticals

EyeCyte
eyecyte.com

Camino Pharma
caminopharma.com

PIN Pharma
pinpharma.com

Imagen Biotech

Panacela Labs
panacelalabs.com

PanTher Therapeutics
panthertx.com

Phigenix
phigenix.com

Pono Pharma

Thetis Pharmaceuticals
thetispharma.com
Companies similar to Phanes Therapeutics include Phoenicis, Pheast Therapeutics, Thesan Pharmaceuticals and PineTree Therapeutics.
Phanes Therapeutics was founded in 2016.
Phanes Therapeutics' headquarters is located in San Diego, CA, US.
Phanes Therapeutics' most recent funding round was for $40M (USD) in May 2021.
As of May 7, 2021, Phanes Therapeutics has raised a total of $40M (USD).
Phanes Therapeutics has 24 employees as of Feb 4, 2024.